{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T17:08:32Z","timestamp":1765991312417,"version":"3.48.0"},"reference-count":22,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>In phase 3 trials, tenofovir alafenamide (TAF) showed antiviral efficacy comparable to that of tenofovir disoproxil fumarate (TDF) for chronic hepatitis B (CHB), with an improved safety profile. This study aimed to compare the clinical efficacy of TAF and TDF in terms of the risk of hepatocellular carcinoma (HCC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a nationwide historical population cohort study on treatment\u2010na\u00efve adult patients with CHB receiving TAF (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200929\u2009309) or TDF (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200958\u2009046) as first\u2010line therapy from 2017 to 2022 using data from the Korean National Health Insurance Service database. Cumulative HCC incidence and associated risk factors were estimated using competing risk factors. Propensity score (PS)\u2010matched analysis was used to minimise the confounding effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 54\u2009185 patients were included in the study, with 20\u2009994 in the TAF group and 33\u2009191 in the TDF group. The annual incidence of HCC was significantly lower in the TAF group (7.5\/1000 patient\u2010years [PYs]) than in the TDF group (10.3\/1000 PYs; subdistribution hazard ratio [SHR], 0.74;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). After PS matching, TAF continued to exhibit a protective effect against HCC (7.5\/1000 PYs vs. 9.9\/1000 PYs;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Multivariable analysis with Fine\u2013Gray proportional subdistribution hazards model identified TAF as significantly associated with a reduced HCC incidence (SHR: 0.76;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Subgroup analysis confirmed the hepatoprotective effect of TAF against HCC even in patients with cirrhosis (SHR: 0.78;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study showed that TAF had a hepatoprotective effect against HCC in patients with CHB, providing valuable guidance for clinicians in selecting the appropriate initial treatment for these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/liv.70357","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:22:08Z","timestamp":1758792128000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Treated With Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate"],"prefix":"10.1111","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1577-1759","authenticated-orcid":false,"given":"Jiwon","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Liver Center Asan Medical Center, University of Ulsan College of Medicine  Seoul Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1878-0215","authenticated-orcid":false,"given":"Jihye","family":"Lim","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine Yeouido St. Mary's Hospital, College of Medicine, the Catholic University of Korea  Seoul Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye\u2010Jee","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Biostatistics Asan Medical Center, University of Ulsan College of Medicine  Seoul Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwa Jung","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Biostatistics Asan Medical Center, University of Ulsan College of Medicine  Seoul Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonggi","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Liver Center Asan Medical Center, University of Ulsan College of Medicine  Seoul Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.11.039"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30107-8"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30024-3"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28156"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0084"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30421-2"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.04.045"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.12.016"},{"key":"e_1_2_13_11_1","unstructured":"H. L. Y.Chan M.Buti K.Agarwal et\u00a0al. \u201cMaintenance of High Levels of Viral Suppression and Improved Safety Profile of Tenofovir Alafenamide (TAF) Relative to Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B Patients Treated for 5\u2009Years in 2 Ongoing Phase 3 Studies \u201dPaper Presented at: The Liver Meeting Digital Experience2020."},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2023.0328"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15261"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100847"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.4070"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13601"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1032-6"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.12997\/jla.2022.11.2.103"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphys.2016.05.008"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-023-02996-w"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i13.2396"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-023-00760-9"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1159\/000096313"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.70357","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T16:42:00Z","timestamp":1765989720000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.70357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1111\/liv.70357"],"URL":"https:\/\/doi.org\/10.1111\/liv.70357","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"type":"print","value":"1478-3223"},{"type":"electronic","value":"1478-3231"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"2025-01-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70357"}}